For example, translational studies performed in the HUDSON phase II trial showed that ATRi AZD6738 could both induce inflammatory- and IFN-associated signatures and decrease exhausted CD8+ T cells in the blood of patients with NSCLC (62). This evidence concerns the gene CD8A and non-small cell lung carcinoma.